Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Zhou, Jun; M. Mahoney, Kathleen; Giobbie‐Hurder, Anita; Zhao, Fengmin; Lee, Sandra; Liao, Xiaoyun; J. Rodig, Scott; Li, Jingjing; Wu, Xinqi; H. Butterfield, Lisa; Piesche, Matthias; P. Manos, Michael; M. Eastman, Lauren; Dranoff, Glenn; J. Freeman, Gordon; Stephen Hodi, F.

doi:10.1158/2326-6066.cir-16-0329

Public

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Published in Cancer Immunology Research • May 18, 2017

Authors:

Jun Zhou

Kathleen M. Mahoney

Anita Giobbie‐Hurder

Abstract

Abstract Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in patients with a variety of cancers. Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell...

Subject

Blockade

Immune checkpoint

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!